- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Modified messenger ribonucleic acid encoding human ornithine
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles
| EU orphan designation number: | EU/3/17/1867
|
| Active ingredient: | Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles |
| Indication: | Treatment of ornithine transcarbamylase deficiency |
| Sponsor: | PhaseRx Ireland, Ltd
20 Harcourt Street, Dublin 2, Ireland |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 24/04/2017 | Orphan designation | EMA/OD/326/16 | (2017)2786 of 20/04/2017 |
CONTACT
EU links
Directorate General Health & Consumers